麻豆国产成人AV在线_午夜国产精品视频在线_99视频精品国产免费观看_美女禁止的网站免费_嘿嘿视频官方在线页面入口页面弹窗免费下载_日本高清专区一区二无线_幸福宝下载深夜释放自己_美女写真福利视频网站

加入收藏 | 設(shè)為首頁 | 聯(lián)系我們

產(chǎn)品搜索

產(chǎn)品分類

聯(lián)系我們

聯(lián)系人：蔣經(jīng)理
電話：4008750250
號碼：
手機(jī)：18066071954
地址：南京市棲霞區(qū)緯地路9號
Email： zhangxiangwen@cobioer.com

產(chǎn)品展示 / PRODUCTS
藥靶細(xì)胞株 > kinase激酶細(xì)胞株 > CBP73195KIF5B（E15）-RET（E12）-Long/BaF3

KIF5B（E15）-RET（E12）-Long/BaF3
名稱 KIF5B（E15）-RET（E12）-Long/BaF3
型號 CBP73195
報(bào)價
特點(diǎn) KIF5B（E15）-RET（E12）-Long/BaF3,母細(xì)胞：BaF3，凍存條件：90% FBS+10% DMSO
  • 詳細(xì)內(nèi)容


CBP73195
I. Introduction

Cell Line Name：

KIF5B(E15)-RET(E12)-Long/BaF3

Host Cell:

BA/F3

Stability:16 passages (in-house test, that not means the cell line will be instable beyond the passages we tested.)

Application:

Anti-proliferation assay and PD assay

Freeze Medium:

90% FBS+10% DMSO

Complete Culture Medium:

RPMI-1640+10%FBS+2ug/ml puromycin

Mycoplasma Status:

Negative

II.Background

Chromosomal rearrangements involving the gene that encodes the RET tyrosine kinase are known oncogenic drivers in 1% to 2% of patients with non–small cell lung cancer (NSCLC). These RET rearrangements occur with characteristic partners, most commonly KIF5B, but also CCDC6, NCOA, TRIM33, CUX1, KIAA1217, FRMD4A, and KIAA1468. They are typically identified in young patients with adenocarcinoma histology and minimal smoking history. Therapeutic targeting of RET-fusion–driven NSCLCs has taken the form of treatment with broad-spectrum tyrosine kinase inhibitors with anti-RET activity, such as cabozantinib (Cabometyx; Cometriq), vandetanib (Caprelsa), lenvatinib (Lenvima), RXDX-105, and sunitinib (Sutent). Cabozantinib and vandetanib have been the most heavily studied multi-kinase inhibitors (MKIs), with response rates of 20% to 50% in largely pretreated patients with RET-rearranged NSCLC. Sunitinib has been used in fewer patients to date with initial results demonstrating a 22% response rate. RXDX-105 has exhibited uniquely impressive response rates (75%) in patients with non–KIF5B-RET-fusion NSCLC, compared with 0% response in patients with KIF5B-RET-fusion–positive NSCLC. BLU-667 has demonstrated an objective response rate of 50% in patients with RET-fusion positive NSCLC, and LOXO-292 reported a 74% ORR in patients with RET-fusion positive NSCLC. Notably, RXDX-105, BLU- 667, and LOXO-292 have all demonstrated some central nervous system activity in these early phase trials. Future directions of RET inhibition in patients with RET-rearranged NSCLC include additional clinical validation of the next generation RET-selective inhibitors RXDX-105, BLU-667, and LOXO-292 and comparing multikinase inhibitors with RET-selective inhibitors to determine the optimal sequencing of RET-targeted therapies.

III. Representative Data

1. WB of KIF5B-RET (K15, R12L)/BaF3

CBP73195 WB.jpg


2. Anti-proliferation assay

CBP73195 fig.jpg


Figure 2. CTG Proliferation Assay of BaF3 KIF5B-Ret (L) Cells (C2).




如果你對CBP73195KIF5B（E15）-RET（E12）-Long/BaF3感興趣，想了解更詳細(xì)的產(chǎn)品信息，填寫下表直接與廠家聯(lián)系：


留言框

  • 產(chǎn)品：

  • 您的單位：

  • 您的姓名：

  • 聯(lián)系電話：

  • 常用郵箱：

  • 省份：

  • 詳細(xì)地址：

  • 補(bǔ)充說明：

  • 驗(yàn)證碼：

    請輸入計(jì)算結(jié)果（填寫阿拉伯?dāng)?shù)字），如：三加四=7

化工儀器網(wǎng)

推薦收藏該企業(yè)網(wǎng)站
蜜臀导航| 日日夜夜草| 国产伦对白刺激精彩露脸| 国产精品喷水| 亚洲成av| 亚洲天天| 天天射天天日天天操| 久久狠狠干| 国产精品 家庭乱伦| 国产美女啪啪视频| 欧美一区二区精品| 久久久久成人片免费观看蜜芽| 中文字幕一区二区三区乱码| 日韩在线观看网站| av电影手机在线观看| 天天干青青| 成人日本A片无码| 豪妇荡乳1一5潘金莲| 精品人妻中文字幕| 一级a一级a爰片免费免免水网|